Relay Therapeutics, Inc.
NASDAQRelay Therapeutics exits its Q1 earnings week with an unusual split: the Street just raised price targets across the board, yet shorts are adding and the stock is down 7% on the week. The analyst move this week is the headline. Three firms raised targets in the 24 hours following earnings — Barclays lifted to $27 from $21, Raymond James moved to $26 from $23, and Citizens nudged to…
RLAY short interest jumps 21.8% in one week to 15.5% of float, hitting highest level in months as biotech stock faces mounting short pressure.
Snapshot as of 22 Jun 2026
Relay Therapeutics exits its Q1 earnings week with an unusual split: the Street just raised price targets across the board, yet shorts are adding and the stock is down 7% on the week. The analyst move this week is the…
Relay Therapeutics heads into its Q1 2026 earnings print today carrying one of the sharpest tensions in small-cap biotech: 16.3% of the free float sold short, yet not a single analyst holds anything other than a…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for RLAY — free to start on ORTEX.
Sign up for free →Open RLAY on ORTEX